Figure 3. Genome constellations for coding-complete influenza A(H3N2) sequences from the 2012/13 influenza epidemic for all clades (A) and for clade 3 (B), Texas, 3 November 2012–8 February 2013 (n =154).

^a These study samples form their own HA monophyly within clade 5.

^b These study samples form their own HA monophyly within clade 3C.2.

^c Of the 13 strains in this constellation that are also in the HA phylogeny, only one strain falls within clade 3C.2.

^d These study samples form their own HA monophyly within clade 3C.3.

^e Please note that each column is evaluated independently and cluster numbering is arbitrary.

The number of samples observed for each genome constellation is provided, along with an HA clade assignment, for all constellations for which at least one sequence was also included in the HA phylogeny (Figure 1). Results are sorted first by HA, followed by NA, PB2, PB1, PA, NP, M, and NS.

1. Genome constellation 1 (orange) segments were defined as sharing 98% nucleotide identity with the A/Perth/16/2009 vaccine strain. Twelve unique genome constellations were identified at the 98% nucleotide identity cut-off, eight of which were observed in the study samples.
2. Clade 3 genome constellation 1 (purple) segments were defined as sharing 99% nucleotide identity with the A/Victoria/361/2011 vaccine strain. 10 unique genome constellations were identified at the 99% nucleotide identity cut-off, nine of which were observed in the study samples.

The authors gratefully acknowledge the 32 originating and submitting laboratories who directly contributed sequences used in the constellation analysis to GISAID: Alaska State Virology Lab; Arizona Department of Health Services; Austin Health, Australia; California Department of Health Services; Canterbury Health Services, New Zealand; US Centers for Disease Control and Prevention; Institute of Medical and Veterinary Science (IMVS), Australia; Institut Pasteur New Caledonia; Iowa State Hygienic Laboratory; John Hunter Hospital, Virology Unit, Clinical Microbiology, Australia; Kentucky Division of Laboratory Services; Melbourne Pathology, Australia; Michigan Department of Community Health; New Mexico Department of Health; New York State Department of Health; Papua New Guinea Institute of Medical Research; Pathwest QE II Medical Centre, Australia; Pennsylvania Department of Health; Puerto Rico Department of Health; Queensland Health Scientific Services, Australia; Research Institute of Tropical Medicine, Philippines; Rhode Island Department of Health; Royal Hobart Hospital, Australia; Southern Nevada Public Health Lab; Spokane Regional Health District, Washington; State of Hawaii Department of Health; Texas Department of State Health Services-Laboratory Services; USAMC-AFRIMS Department of Virology, Cambodia; Utah Department of Health; Victorian Infectious Diseases Reference Laboratory, Australia; WHO Collaborating Centre for Reference and Research on Influenza, Australia; and WHO National Influenza Centre, National Institute of Medical Research (NIMR), United Kingdom.